ReviewAmerican journal of physiology. Gastrointestinal and liver physiology2010
Recent advances in the regulation of cholangiocarcinoma growth.
Review in American journal of physiology. Gastrointestinal and liver physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer.Frontiers in cell and developmental biology · 2021Review
- Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.The American journal of pathology · 2017Article
- Cholangiocarcinoma: New InsightsAsian Pacific journal of cancer prevention : APJCP · 2017Review
- miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.The American journal of pathology · 2017Article
- Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nature reviews. Gastroenterology & hepatology · 2016Article
- Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.The American journal of pathology · 2016Article
- Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.Cancer research · 2015Article
- Bile acid signaling and biliary functions.Acta pharmaceutica Sinica. B · 2015Review
- Raf kinase inhibitor protein inhibits cholangiocarcinoma cell metastasis by downregulating matrix metalloproteinase 9 and upregulating tissue inhibitor of metalloproteinase 4 expression.Oncology letters · 2015Article
- A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.Annals of surgical oncology · 2014Article
- Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.Translational gastrointestinal cancer · 2013Article
- HDAC6 inhibition restores ciliary expression and decreases tumor growth.Cancer research · 2013Article
- Tumor growth effects of rapamycin on human biliary tract cancer cells.European journal of medical research · 2012Article
- Innate immune cells in liver inflammation.Mediators of inflammation · 2012Review
- Survival benefits of surgical resection in recurrent cholangiocarcinoma.Journal of the Korean Surgical Society · 2011Article
- Vitamin D3 regulates cell viability in gastric cancer and cholangiocarcinoma.Anatomy & cell biology · 2011Article
- Molecular pathology of hepatic neoplasms: classification and clinical significance.Pathology research international · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cholangiocarcinomas arise after the neoplastic transformation of the cholangiocytes that line the intra- and extrahepatic biliary epithelium. Symptoms usually do not present until late in the course of the disease, at which time they are relatively resistant to chemotherapeutic agents and as such are difficult to treat and display a poor prognosis. Because of the relative rarity of this disease, the overall volume of research into the molecular pathophysiology associated with this disease is small compared with other more prevalent tumors. However, the incidence of this devastating cancer is on the rise and renewed efforts to understand the pathogenesis of cholangiocarcinoma is needed to design novel therapeutic strategies to combat this disease. This review summarizes the recent advances into our knowledge and understanding of cholangiocarcinoma and highlights potential novel therapeutic strategies that may prove useful to treat this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.